A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms CAPE
- Sponsors AbbVie
- 01 Mar 2019 Planned End Date changed from 27 Feb 2028 to 2 Mar 2028.
- 01 Mar 2019 Planned primary completion date changed from 27 Feb 2028 to 2 Mar 2028.
- 01 Jun 2018 Planned End Date changed from 30 Apr 2030 to 27 Feb 2028.